Global Endocrine Disorders Market, By Diseases (Addison’s Disease, Gigantism, Goiter, Cushing’s Syndrome, Polycystic Ovary Syndrome (PCOS), Diabetes, Acromegaly, and Others), Drug Class (Estrogen, Testosterone, and Progesterone Replacement Therapy), Route of Administration (Oral and Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031.
Endocrine Disorders Market Analysis and Size
The endocrine disorders market is experiencing significant growth fueled by advancements in diagnostic technologies and treatment methods. The latest innovations are enhancing early detection capabilities and improving patient outcomes. This sector's expansion is driven by increasing prevalence, heightened awareness, and robust research into hormone-related conditions, promising a future of more precise therapies and better management strategies.
The global endocrine disorders market size was valued at USD 11.86 billion in 2023, is projected to reach USD 20.99 billion by 2031, with a CAGR of 7.4% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diseases (Addison’s Disease, Gigantism, Goiter, Cushing’s Syndrome, Polycystic Ovary Syndrome (PCOS), Diabetes, Acromegaly, and Others), Drug Class (Estrogen, Testosterone, and Progesterone Replacement Therapy), Route of Administration (Oral and Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (U.S.), Johnson & Johnson Services, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Aurobindo Pharma (India), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Ascendis Pharma A/S (Denmark), and Bio-Rad Laboratories, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Endocrine disorders involve disruptions in hormone production or function within the body's endocrine system. These conditions can affect various organs and bodily functions, the endocrine disorders symptom include fatigue, weight fluctuations, mood swings, and metabolic disturbances. Common disorders include diabetes, thyroid disorders, adrenal gland disorders, and reproductive hormone imbalances. Treatment often involves hormone replacement therapy, medication, or surgical intervention depending on the specific disorder and its severity.
Endocrine Disorders Market Dynamics
Drivers
- Increasing Prevalence of Endocrine Disorders
The increasing prevalence of endocrine disorders, such as diabetes, thyroid disorders, and adrenal disorders, is significantly driving market demand for treatments. For instance, diabetes affects over 400 million people globally, with projections indicating a rise to 700 million by 2045. Similarly, thyroid disorders affect about 200 million people worldwide. This escalating burden underscores the urgent need for advanced therapies and diagnostic solutions, propelling growth in the endocrine disorders market.
- Increasing Telemedicine and Digital Health
The increasing adoption of telemedicine and digital health platforms is significantly driving the endocrine disorders market by enhancing access to specialized healthcare services. Patients can now consult endocrinologists remotely, facilitating timely diagnosis and treatment planning. For instance, platforms such as Teladoc Health and Doctor on Demand offer virtual consultations for diabetes management and thyroid disorders, expanding reach to underserved populations and improving overall patient outcomes in the management of endocrine conditions.
Opportunities
- Technological Innovations in Treatment
Technological innovations in endocrine disorder treatments, such as hormone replacement therapies, biologics, and targeted therapies, are significantly expanding treatment options. For instance, advancements in insulin pumps and continuous glucose monitors have revolutionized diabetes management, providing patients with better control and quality of life. These innovations not only cater to existing patients but also attract investment and interest from healthcare providers and pharmaceutical companies, thereby driving market growth in the sector.
- Advancements in Diagnostic Technologies
Advancements in diagnostic technologies, such as highly sensitive biomarker assays and advanced imaging techniques such as MRI and PET scans, are revolutionizing the early detection and diagnosis of endocrine disorders. For instance, the development of genetic testing for conditions such as multiple endocrine neoplasia (MEN) syndromes allows for precise identification of genetic mutations, enabling tailored treatment plans. These innovations not only improve patient outcomes but also drive market growth by increasing demand for diagnostic tools and specialized treatments.
Restraints/Challenges
- High Cost of Treatment
The high cost of treatments for endocrine disorders, such as hormone replacement therapies and surgeries, creates significant barriers to access for patients lacking adequate insurance or financial resources. This financial burden limits market growth as it restricts the ability of a large segment of the population to afford necessary medical interventions for managing their endocrine conditions.
- Variability in Patient Response
Variability in patient response to hormone therapies presents a significant hurdle in the endocrine disorders market. The lack of standardized treatment protocols tailored to individual needs limits effective management. This variability complicates clinical outcomes and challenges healthcare providers in achieving consistent therapeutic results, potentially impeding market growth due to unpredictable treatment efficacy and patient outcomes.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In August 2022, the U.S. FDA approved the Mira Ovum Wand, an over-the-counter tool for detecting follicle-stimulating hormone (FSH) in urine, aiding women in tracking ovulation
- In July 2022, Watchfrog Laboratory validated a new method under OECD's Test Guideline n°251 (TG n°251). This method, known as RADAR assay TG n°251, detects chemicals disrupting androgenic hormone signaling, enhancing identification of endocrine disruptors
- In May 2022, Inne.io, based in Berlin, secured EUR 9.3 million to expand its hormone-tracking technology. This advancement aims to empower women in monitoring and understanding their reproductive health more effectively
Endocrine Disorders Market Scope
The market is segmented on the basis of diseases, drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diseases
- Addison’s Disease
- Gigantism, Goiter
- Cushing’s Syndrome
- Polycystic Ovary Syndrome (PCOS)
- Diabetes
- Acromegaly
- Others
Drug Class
- Estrogen
- Testosterone
- Progesterone Replacement Therapy
Route of Administration
- Oral
- Parenteral
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Endocrine Disorders Market Regional Analysis/Insights
The market is analyzed and market size insights and trends are provided by country, diseases, drug class, route of administration, distribution channel and end-user as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market in the endocrine disorders market due to the high income of the countries, high prevalence of parathyroid diseases, and advanced healthcare facilities. These factors drive significant demand for innovative treatments and diagnostic solutions in the region.
Asia-Pacific is expected to dominate the endocrine disorders market due to rising cases of diabetes and thyroid disorders, driven by an aging population and lifestyle changes. Enhanced healthcare infrastructure and increased awareness further propel the market, ensuring better diagnosis, treatment, and management of endocrine conditions.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Endocrine Disorders Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Teva Pharmaceutical Industries Ltd. (Israel)
- Mylan N.V. (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Aurobindo Pharma (India)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Ascendis Pharma A/S (Denmark)
- Bio-Rad Laboratories, Inc. (U.S.)
SKU-